Outset Medical Inc. (OM) Prices Primary and Upsized Secondary Public Offering at $53.50/sh
- S&P 500, Dow end at record highs as weak jobs data eases rate worries
- U.S. Added Only 266,000 Jobs in April, Well Below Estimates
- Roku (ROKU) Surges After Crushing Profit Estimates to Prompt an Upgrade to 'Buy' at Loop Capital
- Dollar broadly weaker after U.S. jobs data disappoint
- Square (SQ) Tops Q1 EPS by 25c
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the pricing of an underwritten public offering of 2,500,000 shares of its common stock sold by Outset and 3,444,859 shares of its common stock by certain of its stockholders at a public offering price of $53.50 per share. In addition, Outset and such selling stockholders granted the underwriters a 30-day option to purchase up to an additional 891,728 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The underwriting discounts and commissions will be borne by Outset with respect to the shares it sells in the offering and by the selling stockholders with respect to the shares they sell in the offering. The offering is expected to close on April 13, 2021, subject to the satisfaction of customary closing conditions.
Morgan Stanley, BofA Securities and Goldman Sachs & Co. LLC are acting as joint lead book-running managers for the offering. Stifel and Cowen are acting as co-managers for the offering.
A registration statement on Form S-1 relating to the shares being sold in this offering was filed with and declared effective by the U.S. Securities and Exchange Commission.
The offering is being made only by means of a prospectus. When available, a copy of the prospectus may be obtained from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at email@example.com; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at firstname.lastname@example.org; and Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: email@example.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Waterdrop Inc. (WDH) Prices 30M ADS IPO at $12/ADS
- Five Star Bancorp (FSBC) Prices 5.265M Share IPO at $20/Sh
- Merck (MRK) Declares Record Date and Dividend for the Organon & Co. Spinoff
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesStifel, Goldman Sachs, Morgan Stanley, Cowen & Co, S1, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!